Key facts
- This page summarizes Scott Shuda's Form 4 filing for InfuSystem Holdings, Inc (INFU).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 17 May 2022, 16:57.
Scott Shuda - 17 May 2022 Form 4 Insider Report for InfuSystem Holdings, Inc (INFU)
- Reporting relationship
- Director
- Issuer ticker
- INFU
- Reported as of
- 17 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 17 May 2022, 16:57:37 UTC
- Prior SEC filing
- 12 Oct 2021
- Next SEC filing
- 16 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kevin R. Whitman, Attorney-in-Fact for Scott Shuda
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Scott Shuda filed Form 4 for InfuSystem Holdings, Inc (INFU) on 17 May 2022.
Change
- Previous filing in this sequence was filed on 12 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INFU
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 65,494
- Date
- 17 May 2022
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INFU
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- Price
- $0.000000
- Shares after
- 35,000
- Date
- 17 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- $8.58
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The stock option was issued with an exercise price equal to the Fair Value as defined by the 2021 Equity Plan, which is computed as the closing price of the Company's common stock reported on the NYSE American LLC on the date of grant.
Footnote F2
The option, representing the right to purchase 35,000 shares of InfuSystem Holdings, Inc. common stock, vests on the date of the 2023 annual shareholder meeting.